Modular Medical Announces Partnership with BSI Group for European Regulatory Clearance of Next-Generation Insulin Pump
Modular Medical, Inc., a trailblazing insulin delivery technology company, took a significant step forward in expanding its reach to European markets. The Company announced that BSI Group, a global organization specializing in testing, inspection, and certification services, will serve as the Notified Body for the European regulatory clearance process of Modular Medical’s next-generation insulin pump, the MODD1.
About the MODD1
The MODD1 is a next-generation insulin pump designed with a user-friendly interface and an affordable price point. It is specifically targeted towards “almost-pumpers,” adults who may have considered using an insulin pump but have been deterred by the high cost and complexity of existing options.
Timeline and Expectations
Modular Medical aims to secure European regulatory clearance for the MODD1 by Q1 2026. This milestone comes following the successful FDA clearance of the MODD1 in the United States in late 2024. This achievement marks a crucial step in the Company’s mission to make insulin pump technology accessible to a broader audience.
Impact on Individuals with Diabetes
The entry of the MODD1 into the European market can bring significant benefits for individuals with diabetes. With its affordable price point and user-friendly design, the MODD1 can make insulin pump technology a more viable option for those who have previously been unable to afford or navigate the complexities of existing insulin pumps. This increased accessibility can lead to better diabetes management and improved overall health outcomes.
Global Impact
The success of the MODD1 in European markets could pave the way for its expansion to other regions, such as Asia and South America. This would further increase the accessibility of insulin pump technology to a global audience, potentially reducing the burden of diabetes management for millions of people worldwide.
Conclusion
Modular Medical’s partnership with BSI Group represents a significant step in the Company’s mission to make insulin pump technology more accessible to a broader audience. The expected European regulatory clearance of the MODD1 by Q1 2026 can lead to improved diabetes management and health outcomes for individuals in Europe and potentially, the global community. As the diabetes population continues to grow, the need for affordable and user-friendly insulin pump solutions becomes increasingly important. With the MODD1, Modular Medical is at the forefront of addressing this need and revolutionizing the insulin delivery landscape.
- Modular Medical partners with BSI Group for European regulatory clearance of next-generation insulin pump, MODD1
- Targeted Q1 2026 for European regulatory clearance
- Affordable and user-friendly insulin pump for “almost-pumpers”
- Can lead to improved diabetes management and health outcomes
- Potential for expansion to other regions
